Jazz Pharmaceuticals JAZZ Other Working Capital
Other Working Capital at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's other working capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's other working capital?
- Jazz Pharmaceuticals (JAZZ) reported other working capital of -$3.9M in Q1 2026.
- How has Jazz Pharmaceuticals's other working capital changed year-over-year?
- Jazz Pharmaceuticals's other working capital decreased by 160.0% year-over-year, from $6.5M to -$3.9M.
- What does other working capital mean?
- The net change in miscellaneous short-term operating assets and liabilities.
- How do you interpret other working capital?
- An increase represents a cash outflow from miscellaneous items, while a decrease represents a cash inflow.
- How does other working capital compare across companies?
- Varies significantly by industry; biopharma firms often show fluctuations due to regulatory or clinical trial-related accruals.